Global Digital Breast Tomosynthesis (DBT) Equipment market analysis
DBT (digital breast tomosynthesis), often known as three-dimensional (3-D) mammography or breast tomosynthesis, is an advanced type of breast imaging or mammography that creates 3D photographs of the breasts using a low-dose x-ray device and machine reconstructions.
By 2027, the global digital breast tomosynthesis (DBT) equipment market is expected to be worth US$ 4,212.4 million.
Request a FREE sample copy – Digital Breast Tomosynthesis Equipment market report click here: https://www.coherentmarketinsights.com/insight/request-pdf/3445
Over the forecast period, the rising prevalence of breast cancer will be a major factor driving the global digital breast tomosynthesis (DBT) equipment market. As per Breastcancer.org, around 268,600 new cases of invasive breast cancer and another 62,930 new cases of non-invasive breast cancer will be diagnosed in women in the U.S. in 2019.
The global digital breast tomosynthesis (DBT) equipment market is expected to expand as more people become aware of the importance of early detection of breast cancer. DBT-based screening leads to higher breast cancer diagnosis rates and fewer call-backs (women who are called back from screening for further tests due to an unexpected finding).
In terms of value, North America dominated the global digital breast tomosynthesis (DBT) equipment market in 2019, contributing about 55.1 percent of the market share, followed by Europe.
The growth of the global digital breast tomosynthesis (DBT) equipment market is projected to be hampered by a lack of data about DBT’s efficacy. DBT has not been subjected to any significant trials. To show that DBT has a significant effect in cancer diagnosis, these trials need a wide participant pool.
Furthermore, increased radiologist interpretation time is likely to stymie growth of the global digital breast tomosynthesis (DBT) equipment market. Owing to the large number of images generated (approximately 200 vs. four for 2D view), reading DBT image sets takes about twice as long as reading 2D mammograms.
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/3445
Patients are subject to more radiation during DBT than they are during 2D mammography. As a result, participants in the global digital breast tomosynthesis (DBT) equipment market should expect attractive growth prospects as radiation exposure is reduced.
Regulatory authorities may also describe the use of DBT in breast cancer screening (group and individual) as well as its use in breast cancer diagnosis and staging (multiple lesions).
The hospitals segment of the global digital breast tomosynthesis (DBT) equipment market was worth US$ 968.6 million in 2019 and is projected to grow at a CAGR of 14.5 percent to US$ 2,866.8 million by 2027.
To broaden their product line, key market players are focusing on partnering and collaborating. Planmed Oy, a Finnish medical technology firm, teamed up with IBEX Innovations Ltd., a UK-based medical X-ray product solutions provider, in January 2020 to combine the IBEX Trueview gridless scatter correction software with Planmed Clarity optical mammography systems.
The growth of the global digital breast tomosynthesis (DBT) equipment market is projected to be supported by R&D in DBT. Researchers from Northeastern University had officially proposed the first near-field radar imaging experimental device that can be used in a co-registered manner with the DBT computer at Massachusetts General Hospital in January 2018.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/digital-breast-tomosynthesis-equipment-market-2794
Key companies contributing in the global digital breast tomosynthesis (DBT) equipment market are GE Healthcare, Internazionale Medico Scientifica S.r.l, Hologic, Inc., Planmed OY, Fujifilm Corporation, and Siemens Healthineers.
To broaden their product line, key market players are focusing on partnering and collaborating. Planmed Oy had partnered with Disior Oy in November 2018 to integrate Disior’s orthopaedic research program with Planmed’s high-tech CBCT (Cone Beam Computed Tomography) scanner, Planmed Verity.
Key companies in the market are now concentrating on product launches in order to broaden their product range. At the 105th annual meeting of the Radiological Society of North America in December 2019, FUJIFILM Medical Systems U.S.A., Inc., a member of the Fujifilm Healthcare portfolio, included three new optical x-ray suites to its portfolio of imaging technologies – FDR Clinica U, FDR Clinica X, and D-EVO Suite FSx (RSNA).
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027